INDUSTRY BRIEFING: Excessive Pricing and the Expanding Boundaries of Competition Law

As scrutiny of pharmaceutical pricing intensifies, excessive pricing is emerging as a tangible enforcement risk within European competition law. Using the AbbVie v. PAF case in the Netherlands as a case study, this presentation explores how courts and authorities are reassessing pricing conduct and what this means for your future strategy.